Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 9/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21905570 | 0.86 | MAPT (0.68) | MAPTTP53SMN1; SMN2THRBALDH1A1 | |
| SCHEMBL4056244 | 0.85 | HDAC1 (0.75) | HDAC1HDAC6MAPTTP53SMN1; SMN2 | |
| SCHEMBL19278554 | 0.84 | HDAC1 (1.00) | HDAC1HDAC6MAPTTP53SMN1; SMN2 | |
| SCHEMBL29159252 | 0.80 | SIRT1 (0.51) | HDAC1HDAC6MAPTTP53ALDH1A1 | |
| SCHEMBL18619540 | 0.79 | MAPT (0.57) | MAPTTP53SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3856028 | 0.79 | HDAC6 (0.60) | HDAC1HDAC6MAPTPOLBALDH1A1 | |
| SCHEMBL23950277 | 0.77 | HDAC1 (1.00) | HDAC1HDAC6 | |
| SCHEMBL3964822 | 0.77 | HDAC1 (0.55) | HDAC1HDAC6ALDH1A1SIRT1 | |
| SCHEMBL19260282 | 0.77 | HDAC1 (0.73) | HDAC1HDAC6MAPTPOLBALDH1A1 | |
| SCHEMBL26159147 | 0.77 | HDAC1 (0.72) | HDAC1HDAC6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416633-B1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | UNIV ILLINOIS (US) | 2025-07-23 | — | — | EP | disclosed |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2017142883-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-08-24 | — | — | WO | disclosed |
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | disclosed |
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7482372-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-6906053-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-6890915-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040132693-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-07-08 | — | — | US | disclosed |
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| US-20030229084-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | disclosed |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | disclosed |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, MMP1, ADAM17 | HDAC1 57/4885HDAC6 249/4885MAPT 4213/4885 |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | HDAC1 490/4885HDAC6 431/4885MAPT 3924/4885 |
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | HDAC1 85/4885HDAC6 225/4885MAPT 4051/4885 |
| US-20030229084-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | TNF, MMP3, TIMP3 | HDAC1 377/4885HDAC6 877/4885MAPT 2045/4885 |
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC5, HDAC7 | HDAC1 1/4885HDAC6 8/4885MAPT 751/4885 |
| US-20040132693-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | HDAC1 490/4885HDAC6 431/4885MAPT 3924/4885 |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | HDAC1, HDAC5, HDAC7 | HDAC1 1/4885HDAC6 8/4885MAPT 751/4885 |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | HDAC1 85/4885HDAC6 225/4885MAPT 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.